Why the study?
The interplay between chronic kidney disease and coronary artery disease on cardiovascular event incidence in patients with suspected chronic coronary syndrome was not well characterized.
Does the absence of coronary artery disease predict a lower risk of major adverse cardiovascular events in patients with chronic kidney disease and suspected chronic coronary syndrome?
Cohort (n=42,611)
Does the absence of coronary artery disease predict a lower risk of major adverse cardiovascular events in patients with chronic kidney disease and suspected chronic coronary syndrome?
Relative Risk: 3.57 (95% CI 1.92–6.67)
Absolute Event Rate: 2.27% vs 0.52%
The absence of coronary artery disease on angiography is a strong negative predictor of major adverse cardiovascular events, even in patients with severe chronic kidney disease.
Absence of CAD marks substantially lower MACE risk across CKD stages; extends observational data but should not yet alter risk stratification or management.
Purpose: To investigate the interplay between chronic kidney disease (CKD) and coronary artery disease (CAD) on the incidence of cardiovascular events in patients with suspected chronic coronary syndrome (CCS). Patients and Methods: Patients with suspected CCS who underwent first-time coronary angiography in Western Denmark between 2003 and 2016 were included in this cohort study. Moreover, an age- and sex-matched general population cohort was established. Patients were stratified according to estimated glomerular filtration rate (eGFR). Presence of CAD was defined as ≥ 1 obstructive stenosis or non-obstructive diffuse disease. Major adverse cardiovascular events (MACE) were defined as a composite of myocardial infarction, ischemic stroke, and cardiac death. Results: A total of 42,611 patients were included with a median follow-up of 7.3 years. Patients without and with CAD had MACE rates per 100 person-years that were 0.52 and 1.67 for eGFR ≥ 90 mL/min/1.73 m 2 , 0.68 and 2.09 for eGFR 60– 89 mL/min/1.73 m 2 , 1.27 and 3.85 for eGFR 30– 59 mL/min/1.73 m 2 , and 2.27 and 6.92 for eGFR < 30 mL/min/1.73 m 2 . Comparing to eGFR ≥ 90 mL/min/1.73 m 2 , the adjusted incidence rate ratios for MACE were 1.29 (1.10– 1.51) for eGFR 60– 89 mL/min/1.73 m 2 , 1.86 (1.49– 2.33) for eGFR 30– 59 mL/min/1.73 m 2 , and 3.57 (1.92– 6.67) for eGFR < 30 mL/min/1.73 m 2 in patients without CAD, and 1.11 (1.03– 1.20), 1.71 (1.55– 1.90), and 2.46 (1.96– 3.09) in patients with CAD. The inverse relationship between kidney function and risk of MACE was confirmed when comparing patients with and without CAD to matched individuals in the general population. Conclusion: Absence of CAD is a strong negative predictor of major adverse cardiovascular events in patients with CKD.
No takes yet. Share an insight, caveat, or question.
Tonnesen et al. (2023) conducted a cohort in Suspected chronic coronary syndrome (n=42,611). Decreased eGFR (< 30 mL/min/1.73 m2) without CAD vs. eGFR ≥ 90 mL/min/1.73 m2 without CAD was evaluated on Major adverse cardiovascular events (MACE) (composite of myocardial infarction, ischemic stroke, and cardiac death) (IRR 3.57, 95% CI 1.92-6.67).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: